Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Collegium Pharma (COLL)

Collegium Pharma (COLL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 877,323
  • Shares Outstanding, K 35,248
  • Annual Sales, $ 310,020 K
  • Annual Income, $ 26,750 K
  • 60-Month Beta 0.96
  • Price/Sales 2.84
  • Price/Cash Flow 9.79
  • Price/Book 5.18
Trade COLL with:

Options Overview

Details
  • Implied Volatility 53.60%
  • Historical Volatility 23.43%
  • IV Percentile 13%
  • IV Rank 42.03%
  • IV High 122.45% on 08/06/20
  • IV Low 3.68% on 06/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 953
  • Open Int (30-Day) 826

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.34
  • Number of Estimates 4
  • High Estimate 0.41
  • Low Estimate 0.28
  • Prior Year 0.23
  • Growth Rate Est. (year over year) +47.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.20 +13.74%
on 07/08/21
25.63 -1.48%
on 07/22/21
+1.95 (+8.37%)
since 07/02/21
3-Month
21.27 +18.71%
on 05/11/21
25.66 -1.60%
on 06/25/21
+2.26 (+9.83%)
since 05/03/21
52-Week
16.14 +56.44%
on 08/04/20
26.91 -6.17%
on 02/10/21
+8.60 (+51.65%)
since 08/03/20

Most Recent Stories

More News
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss...

COLL : 25.25 (+1.16%)
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of Paul Brannelly as Chief Financial Officer. Mr. Brannelly...

COLL : 25.25 (+1.16%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 122.12 (+0.99%)
ACRX : 1.2000 (-0.83%)
ACOR : 3.87 (+4.03%)
AXSM : 49.18 (-2.27%)
BAYRY : 14.9500 (+0.20%)
BDRFF : 118.2500 (-1.21%)
BDSI : 3.90 (+1.83%)
BMY : 69.31 (+1.90%)
COLL : 25.25 (+1.16%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3500 (-2.88%)
EGLT : 0.0315 (-63.37%)
LLY : 255.99 (+3.81%)
FLXN : 6.04 (-3.36%)
GLPG : 61.00 (-0.75%)
HRTX : 11.93 (-3.48%)
KMPH : 9.89 (-3.98%)
MRK : 76.41 (+0.30%)
MESO : 7.41 (+4.22%)
NKTR : 15.80 (-1.00%)
NVS : 92.71 (+0.48%)
ORXOY : 4.5350 (+1.91%)
PFE : 45.68 (+3.91%)
REGN : 586.51 (+1.63%)
VRX.TO : 30.80 (-3.33%)
Collegium Announces Publication of Real-World Data in Journal of Pain Research

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of...

COLL : 25.25 (+1.16%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 122.12 (+0.99%)
ACRX : 1.2000 (-0.83%)
ACOR : 3.87 (+4.03%)
AXSM : 49.18 (-2.27%)
BAYRY : 14.9500 (+0.20%)
BDRFF : 118.2500 (-1.21%)
BDSI : 3.90 (+1.83%)
BMY : 69.31 (+1.90%)
COLL : 25.25 (+1.16%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3500 (-2.88%)
EGLT : 0.0315 (-63.37%)
LLY : 255.99 (+3.81%)
FLXN : 6.04 (-3.36%)
GLPG : 61.00 (-0.75%)
HRTX : 11.93 (-3.48%)
KMPH : 9.89 (-3.98%)
MRK : 76.41 (+0.30%)
MESO : 7.41 (+4.22%)
NKTR : 15.80 (-1.00%)
NVS : 92.71 (+0.48%)
ORXOY : 4.5350 (+1.91%)
PFE : 45.68 (+3.91%)
REGN : 586.51 (+1.63%)
VRX.TO : 30.80 (-3.33%)
Collegium to Participate in Upcoming Investor Conference

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following...

COLL : 25.25 (+1.16%)
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?...

COLL : 25.25 (+1.16%)
Collegium Pharmaceutical: Q1 Earnings Snapshot

STOUGHTON, Mass. (AP) _ Collegium Pharmaceutical Inc. (COLL) on Thursday reported first-quarter profit of $15.7 million.

COLL : 25.25 (+1.16%)
Collegium Reports Record Quarterly Revenue of $87.7 Million

- Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 -

COLL : 25.25 (+1.16%)
Collegium Pharmaceutical, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30...

COLL : 25.25 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171,...

See More

Key Turning Points

3rd Resistance Point 26.05
2nd Resistance Point 25.70
1st Resistance Point 25.48
Last Price 25.25
1st Support Level 24.91
2nd Support Level 24.56
3rd Support Level 24.34

See More

52-Week High 26.91
Last Price 25.25
Fibonacci 61.8% 22.80
Fibonacci 50% 21.52
Fibonacci 38.2% 20.25
52-Week Low 16.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar